Biochem. Soc. Trans. (2020) 48 (5): 2253–2259 DOI: https://doi.org/10.1042/BST20200523
The authors of this paper would like to make the following correction to the citations within the text:
Reference 48 was a duplication of reference 12 and should have instead cited Bersuker, K., Hendricks, J.M., Li, Z. et al. (2019) The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis Nature575, 688–692. DOI: 10.1038/s41586-019-1705-2
In the section entitled “The FSP1 ubiquinone system”
The FSP1-ubiquinone axis was then characterized as a GSH/GPX4 independent ferroptosis-suppressing pathway that exemplifies an elegant system for the enzymatic regeneration of endogenous antioxidants [47].
Should instead cite the following:
The FSP1-ubiquinone axis was then characterized as a GSH/GPX4 independent ferroptosis-suppressing pathway that exemplifies an elegant system for the enzymatic regeneration of endogenous antioxidants [47, 48].
In the section entitled “The tetrahydrobiopterin-DHFR system”
More recently, another novel endogenous antioxidant system has been identified. Using CRISPR activation screens, a study identified tetrahydrobiopterin (BH4) as an essential metabolite supporting the proliferation of cancer cell lines challenged with the GPX4 inhibitor RSL3 [48].
Should have cited
More recently, another novel endogenous antioxidant system has been identified. Using CRISPR activation screens, a study identified tetrahydrobiopterin (BH4) as an essential metabolite supporting the proliferation of cancer cell lines challenged with the GPX4 inhibitor RSL3 [11, 12].
At the end of the article, the final sentence
Hence, these studies demonstrate that DHFR should be regarded as an important regulator of ferroptosis, while its inhibitor methotrexate, a common chemotherapeutic agent, could be a promising therapeutic option for ferroptotic anti-cancer therapies [48]
Should have read
Hence, these studies demonstrate that DHFR should be regarded as an important regulator of ferroptosis, while its inhibitor methotrexate, a common chemotherapeutic agent, could be a promising therapeutic option for ferroptotic anti-cancer therapies [12].
